In addition, the expression of granzyme B (GZMB) and genes involved in CD8+ TRM cell activation has been shown to be lower with EGFR-MT than the wild type, indicating that CD8+ TRM cells in EGFR-MT tumors have a lower anti-neoplastic activity to kill cancer cells (29). This evidence concerns the gene GZMB and cancer.